Edition:
India

EyeGate Pharmaceuticals Inc (EYEG.OQ)

EYEG.OQ on NASDAQ Stock Exchange Capital Market

0.52USD
13 Aug 2018
Change (% chg)

-- (--)
Prev Close
$0.52
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
225,662
52-wk High
$1.38
52-wk Low
$0.29

Chart for

About

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone... (more)

Overall

Beta: --
Market Cap(Mil.): $20.99
Shares Outstanding(Mil.): 17.20
Dividend: --
Yield (%): --

Financials

  EYEG.OQ Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -1.30 -- --
ROI: -193.34 15.07 14.61
ROE: -241.44 16.60 16.33

BRIEF-Armistice Capital LLC Reports 50.8 Pct Stake In Eyegate Pharmaceuticals As Of April 13

* ARMISTICE CAPITAL LLC REPORTS 50.8 PERCENT STAKE IN EYEGATE PHARMACEUTICALS INC AS OF APRIL 13 - SEC FILING

23 Apr 2018

BRIEF-Eyegate Announces $11.25 Million Public Offering

* PRICING OF PUBLIC OFFERING OF 35.2 MILLION SHARES OF COMMON STOCK AND WARRANTS TO PURCHASE 35.2 MILLION SHARES OF COMMON STOCK

13 Apr 2018

BRIEF-EyeGate Issued New Patent For Iontophoretic Contact Lens Technology

* EYEGATE ISSUED NEW PATENT FOR IONTOPHORETIC CONTACT LENS TECHNOLOGY Source text for Eikon: Further company coverage:

11 Apr 2018

BRIEF-Eyegate Receives FDA Feedback On Investigational Device Exemption Amendment For Second Pilot Study Of Ocular Bandage Gel

* EYEGATE RECEIVES FDA FEEDBACK ON INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR SECOND PILOT STUDY OF OCULAR BANDAGE GEL

09 Apr 2018

BRIEF-EyeGate Gets Milestone Payment For Confirmatory Study Of Eye Inflammation Treatment

* EYEGATE COMPLETES ENROLLMENT AND RECEIVES MILESTONE PAYMENT FOR CONFIRMATORY PHASE 3 CLINICAL STUDY OF EGP-437 IN ANTERIOR UVEITIS Source text for Eikon: Further company coverage:

06 Apr 2018

BRIEF-Eyegate Pharmaceuticals Files For Potential Mixed Shelf Of Up To $20 Mln

* EYEGATE PHARMACEUTICALS FILES FOR POTENTIAL MIXED SHELF OF UP TO $20 MILLION - SEC FILING Source text: (https://bit.ly/2ugghJy) Further company coverage:

24 Mar 2018

BRIEF-Eyegate Pharma Submits Investigational Device Exemption Amendment For Second Pilot Study Of Ocular Bandage Gel

* EYEGATE PHARMA SUBMITS INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR SECOND PILOT STUDY OF OCULAR BANDAGE GEL

08 Mar 2018

Earnings vs. Estimates